Back

Arrowhead’s plozasiran gains $215 million priority review voucher

Verifying
  • Arrowhead Pharmaceuticals is preparing plozasiran to compete with Ionis in severe hypertriglyceridemia treatment.
  • Plozasiran benefits from a $215 million priority review voucher for faster market launch.
  • Phase III trials SHASTA-3 and SHASTA-4 are cited in the development program.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Arrowhead’s plozasiran gains $215 million priority review voucher - CoinPost Terminal